未登录

J

Jessica Wojciechowski

pumasai inc

H指数:9

被引数:329

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Latent Variable Indirect Response Modeling of Cendakimab Exposure–Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework

cpt: pharmacometrics & systems pharmacology

IF0

2026-01-230

OAAI

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B

血友病B患者接受Fidanacogene Elaparvovec基因疗法后因子IX活性的人群建模

Clinical Pharmacokinetics

IF4

2025-08-010

OA

Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection

综合安全性暴露-反应分析以支持Ritlecitinib剂量选择

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-05-120

OA

Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-11-200

OA

Automated Poisson regression exposure-response analysis for binary outcomes with PoissonERM

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-07-310

OA

Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-04-162

OAAI

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics

IF3.7

2023-03-288

OAAI

Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-03-166

OAAI

Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-10-046

OAAI

Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-04-118

OA

Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-02-176

OA

Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming

IF3.7

2018-06-1416

OAAI

Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies

IF3.7

2017-04-2530

PREAI

Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-03-019

OA

A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-04-070

OAAI

A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine

甲氨蝶呤，柳氮磺吡啶和羟氯喹治疗期间早期类风湿关节炎疾病活动的人群模型

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2015-04-226

OAAI

Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside

IF3.7

2014-06-2041

OA